GLP-1 (glucagon-like peptide-1) receptor agonists are a class of drugs that mimic the effects of the naturally occurring incretin hormone GLP-1. They bind to GLP-1 receptors in the pancreas, gut, brain, and heart, producing effects that include increased insulin secretion, decreased glucagon release, slowed gastric emptying, and importantly, significant appetite suppression and weight reduction. Approved examples include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda).
Few peptides have crossed from research niche into mainstream cultural conversation as dramatically as the GLP-1 receptor agonists. Semaglutide and tirzepatide aren't just drugs anymore — they've become social phenomena, showing up in earnings calls, celebrity interviews, and congressional hearings. That visibility is both a strength and a problem: actual data gets buried under commentary.
This guide strips that back. Here's what the clinical trials actually showed, where the genuine scientific uncertainty lies, and why the GLP-1 class matters to anyone interested in the broader peptide research landscape.
Important distinction. Unlike most peptides discussed on WolveStack, the major GLP-1 agonists (semaglutide, tirzepatide, liraglutide) are FDA-approved prescription drugs. They are not research chemicals. This article is educational. Access requires a prescription from a licensed clinician.
What GLP-1 Actually Does in the Body
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by L-cells in the small intestine in response to food intake. The natural molecule has a half-life of 2–3 minutes — broken down rapidly by the enzyme DPP-4. GLP-1 receptor agonists are synthetic analogs engineered to resist DPP-4 degradation, producing sustained GLP-1 receptor activation from hours to weeks depending on formulation.
GLP-1 receptors are expressed in multiple tissues. The effects matter:
Pancreas: Stimulates insulin secretion in a glucose-dependent manner (lowers risk of hypoglycemia compared to older diabetes drugs). Suppresses glucagon. Improves beta cell function over time.
Gut: Slows gastric emptying, delaying glucose absorption and reducing post-meal blood sugar spikes. Reduces gut motility.
Brain: Activates GLP-1 receptors in the hypothalamus and brainstem, producing powerful satiety signaling. This central appetite suppression is likely the primary driver of the dramatic weight loss seen in clinical trials.
Heart: GLP-1 receptors in cardiac tissue appear to have cardioprotective effects — multiple large cardiovascular outcome trials have now demonstrated reduced major cardiovascular events in high-risk patients.
The Clinical Trial Data
The STEP clinical trial program for semaglutide (Wegovy) and the SURMOUNT program for tirzepatide (Zepbound) represent some of the largest weight management trials ever conducted. The results weren't marginal. Prior to GLP-1 agonists, lifestyle interventions and approved weight loss medications typically produced 5–8% weight loss. The GLP-1 class effectively tripled or quadrupled that benchmark.
The SELECT trial, published in 2023, was a cardiovascular outcomes trial of semaglutide in adults with obesity and established cardiovascular disease (but without diabetes). The 26% reduction in MACE (major adverse cardiovascular events) over 3.3 years — independent of glycemic control — was a landmark finding. It suggests the cardioprotective effect isn't just about blood sugar management.
Semaglutide vs. Tirzepatide: How They Differ
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Weight loss (avg, max dose) | ~15% (STEP 1) | ~22% (SURMOUNT-1) |
| Diabetes approval | Ozempic (0.5–2 mg weekly) | Mounjaro (2.5–15 mg weekly) |
| Obesity approval | Wegovy (2.4 mg weekly) | Zepbound (2.5–15 mg weekly) |
| Cardiovascular outcome data | SUSTAIN-6, SELECT trials | SURPASS-CVOT (ongoing) |
| GI side effects | Common (nausea, vomiting) | Similar, possibly less severe |
The Compounded Semaglutide Question
When Ozempic and Wegovy faced severe supply shortages (2022–2024), the FDA placed them on the drug shortage list. This allowed licensed compounding pharmacies to legally produce compounded versions of semaglutide. The FDA has since removed semaglutide from the shortage list, which effectively ended the legal basis for most compounded semaglutide production.
Beyond the regulatory shift, there's a substantive scientific concern: many compounded preparations used semaglutide sodium or semaglutide acetate — salt forms that are pharmacologically distinct from the base compound in approved Ozempic/Wegovy. The FDA issued explicit warnings noting these salt forms haven't been studied for safety and efficacy and aren't the same as the approved drug.
Safety note. The FDA has received adverse event reports involving compounded semaglutide products, including some involving semaglutide salt forms. If considering GLP-1 therapy, the approved prescription products (Wegovy, Zepbound) remain the only versions with established safety and efficacy profiles. This is one space where the research chemical analogy doesn't apply — these are approved drugs with prescription requirements for good reason.
Beyond Weight: Emerging Research Areas
The GLP-1 receptor's broad distribution has prompted research into applications well beyond diabetes and obesity. Several large trials are currently underway or recently reported:
Fatty liver disease (MASH): Semaglutide showed statistically significant improvement in MASH resolution in Phase 3 trials. Regulatory approval for this indication was under review as of 2025.
Sleep apnea: The SURMOUNT-OSA trial showed tirzepatide significantly reduced apnea-hypopnea index (AHI) scores in adults with obesity-related sleep apnea — an effect likely mediated through weight loss and potentially direct airway tissue effects.
Neurodegenerative disease: GLP-1 receptors in the brain have prompted trials in Alzheimer's and Parkinson's disease. The EVOKE and EVOKE+ trials with semaglutide in early Alzheimer's completed enrollment. Mechanistic rationale includes GLP-1's anti-inflammatory and neuroprotective effects.
Addiction: Preclinical data showing GLP-1 agonists reduce alcohol and drug seeking behavior in rodents has generated substantial clinical trial activity. Early human data in alcohol use disorder looks promising; larger trials are ongoing.
Kidney disease: The FLOW trial (semaglutide in chronic kidney disease) was stopped early due to clear benefit — a regulatory milestone that led to expanded labeling.
What This Means for the Peptide Research Community
The GLP-1 story is in some ways the opposite of most peptide research narratives: here you have rigorous Phase 3 data, FDA approval, large cardiovascular outcome trials, and billions in annual revenue — followed by a cultural backlash about "easy" weight loss, supply crises, and gray market compounding activity.
For those interested in the research peptide space more broadly, the GLP-1 class is a useful case study. It demonstrates what actually happens when a peptide mechanism with genuine preclinical promise makes it through the full clinical trial pipeline. The evidence is stronger, the risks are better characterized, and the regulatory picture is clearer — but so is the gatekeeping around access.
Research-Grade Sourcing
WolveStack partners with Ascension Peptides for independently third-party tested research compounds with published COAs.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
GLP-1 receptor agonists are drugs that mimic the effects of the naturally occurring incretin hormone GLP-1. They bind to GLP-1 receptors in the pancreas, gut, brain, and heart, producing effects including increased insulin secretion, slowed gastric emptying, and powerful appetite suppression. Approved examples include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).
In the STEP 1 trial, patients on semaglutide 2.4 mg weekly lost an average of 14.9% of body weight over 68 weeks, versus 2.4% for placebo. More than 86% of participants lost at least 5% of body weight. The SURMOUNT-1 trial for tirzepatide showed even larger effects: up to 22.5% body weight reduction at the highest dose.
Semaglutide activates only the GLP-1 receptor. Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both GLP-1 and the glucose-dependent insulinotropic polypeptide (GIP) receptor. The dual mechanism of tirzepatide appears to produce greater weight loss than semaglutide in available data, though both show substantial clinical efficacy.
GLP-1 receptor agonists have meaningful long-term safety data from their use in type 2 diabetes management. Large cardiovascular outcome trials showed cardioprotective effects. Common adverse effects are gastrointestinal and typically diminish with dose titration. Rare concerns include pancreatitis risk and theoretical thyroid C-cell tumor risk seen in rodent studies but not yet confirmed in humans at clinical doses.
During the drug shortage period, the FDA permitted compounding pharmacies to produce compounded semaglutide. Many used salt forms (semaglutide sodium or acetate) that are pharmacologically distinct from the approved compound. The FDA has issued warnings about these salt forms and removed semaglutide from the shortage list, ending most legal basis for compounding. The FDA has received adverse event reports involving compounded semaglutide products.
Emerging research is investigating GLP-1 agonists for MASH/fatty liver disease, Alzheimer's disease, addiction, sleep apnea, and kidney disease. The FLOW trial (semaglutide in CKD) was stopped early due to clear benefit. Whether these applications will all reach approval is being determined — but the breadth of potential indications reflects how widely GLP-1 receptors are distributed in the body.
New to the peptide research space? Our beginner's guide covers the landscape — from research chemicals to prescription biologics. For the recovery-focused peptides like BPC-157 and TB-500, see the Wolverine Stack.